The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis

Antimicrobial Resistance Collaborators,Gisela Robles Aguilar,Lucien R Swetschinski,Nicole Davis Weaver,Kevin S Ikuta,Tomislav Mestrovic,Authia P Gray,Erin Chung,Eve E Wool,Chieh Han,Anna Gershberg Hayoon,Daniel T Araki,Ashkan Abdollahi,Ahmed Abu-Zaid,Mohammad Adnan,Ramesh Agarwal,Javad Aminian Dehkordi,Aleksandr Y Aravkin,Demelash Areda,Ahmed Y Azzam,Eitan N Berezin,Akshaya Srikanth Bhagavathula,Zulfiqar A Bhutta,Soumitra S Bhuyan,Annie J Browne,Carlos A Castañeda-Orjuela,Eeshwar K Chandrasekar,Patrick R Ching,Xiaochen Dai,Gary L Darmstadt,Fernando Pio De la Hoz,Nancy Diao,Daniel Diaz,Wendel Mombaque Dos Santos,David Eyre,Coralith Garcia,Georgina Haines-Woodhouse,Mohammed Bheser Hassen,Nathaniel J Henry,Susan Hopkins,Md Mahbub Hossain,Kenneth Chukwuemeka Iregbu,Chidozie Cd Iwu,Jan Adriaan Jacobs,Mark M Janko,Ronald Jones,Ibraheem M Karaye,Ibrahim A Khalil,Imteyaz A Khan,Taimoor Khan,Jagdish Khubchandani,Suwimon Khusuwan,Adnan Kisa,Giscard Wilfried Koyaweda,Fiorella Krapp,Emmanuelle Ap Kumaran,Hmwe Hmwe Kyu,Stephen S Lim,Xuefeng Liu,Stephen Luby,Sandeep B Maharaj,Christopher Maronga,Miquel Martorell,Jürgen May,Barney McManigal,Ali H Mokdad,Catrin E Moore,Ebrahim Mostafavi,Efrén Murillo-Zamora,Marisa Marcia Mussi-Pinhata,Ruchi Nanavati,Hasan Nassereldine,Zuhair S Natto,Farah Naz Qamar,Virginia Nuñez-Samudio,Theresa J Ochoa,Tolulope R Ojo-Akosile,Andrew T Olagunju,Antonio Olivas-Martinez,Edgar Ortiz-Brizuela,Pradthana Ounchanum,Jose L Paredes,Venkata Suresh Patthipati,Shrikant Pawar,Marcos Pereira,Andrew Pollard,Alfredo Ponce-De-Leon,Elton Junio Sady Prates,Ibrahim Qattea,Luis Felipe Reyes,Emmanuel Roilides,Victor Daniel Rosenthal,Kristina E Rudd,Weerawut Sangchan,Samroeng Seekaew,Allen Seylani,Niloufar Shababi,Sunder Sham,Jose Sifuentes-Osornio,Harpreet Singh,Andy Stergachis,Nidanuch Tasak,Nathan Y Tat,Areerat Thaiprakong,Pascual R Valdez,Dereje Y Yada,Ismaeel Yunusa,Mikhail Sergeevich Zastrozhin,Simon I Hay,Christiane Dolecek,Benn Sartorius,Christopher Jl Murray,Mohsen Naghavi

DOI: https://doi.org/10.1016/j.lana.2023.100561

2023-08-08

Abstract:Background: Antimicrobial resistance (AMR) is an urgent global health challenge and a critical threat to modern health care. Quantifying its burden in the WHO Region of the Americas has been elusive-despite the region's long history of resistance surveillance. This study provides comprehensive estimates of AMR burden in the Americas to assess this growing health threat. Methods: We estimated deaths and disability-adjusted life-years (DALYs) attributable to and associated with AMR for 23 bacterial pathogens and 88 pathogen-drug combinations for countries in the WHO Region of the Americas in 2019. We obtained data from mortality registries, surveillance systems, hospital systems, systematic literature reviews, and other sources, and applied predictive statistical modelling to produce estimates of AMR burden for all countries in the Americas. Five broad components were the backbone of our approach: the number of deaths where infection had a role, the proportion of infectious deaths attributable to a given infectious syndrome, the proportion of infectious syndrome deaths attributable to a given pathogen, the percentage of pathogens resistant to an antibiotic class, and the excess risk of mortality (or duration of an infection) associated with this resistance. We then used these components to estimate the disease burden by applying two counterfactual scenarios: deaths attributable to AMR (compared to an alternative scenario where resistant infections are replaced with susceptible ones), and deaths associated with AMR (compared to an alternative scenario where resistant infections would not occur at all). We generated 95% uncertainty intervals (UIs) for final estimates as the 25th and 975th ordered values across 1000 posterior draws, and models were cross-validated for out-of-sample predictive validity. Findings: We estimated 569,000 deaths (95% UI 406,000-771,000) associated with bacterial AMR and 141,000 deaths (99,900-196,000) attributable to bacterial AMR among the 35 countries in the WHO Region of the Americas in 2019. Lower respiratory and thorax infections, as a syndrome, were responsible for the largest fatal burden of AMR in the region, with 189,000 deaths (149,000-241,000) associated with resistance, followed by bloodstream infections (169,000 deaths [94,200-278,000]) and peritoneal/intra-abdominal infections (118,000 deaths [78,600-168,000]). The six leading pathogens (by order of number of deaths associated with resistance) were Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Together, these pathogens were responsible for 452,000 deaths (326,000-608,000) associated with AMR. Methicillin-resistant S. aureus predominated as the leading pathogen-drug combination in 34 countries for deaths attributable to AMR, while aminopenicillin-resistant E. coli was the leading pathogen-drug combination in 15 countries for deaths associated with AMR. Interpretation: Given the burden across different countries, infectious syndromes, and pathogen-drug combinations, AMR represents a substantial health threat in the Americas. Countries with low access to antibiotics and basic health-care services often face the largest age-standardised mortality rates associated with and attributable to AMR in the region, implicating specific policy interventions. Evidence from this study can guide mitigation efforts that are tailored to the needs of each country in the region while informing decisions regarding funding and resource allocation. Multisectoral and joint cooperative efforts among countries will be a key to success in tackling AMR in the Americas. Funding: Bill & Melinda Gates Foundation, Wellcome Trust, and Department of Health and Social Care using UK aid funding managed by the Fleming Fund.